Publications by authors named "Jinfan Qiu"
Article Synopsis
- Treatment options for ALK-positive NSCLC patients are limited and often involve chemotherapy, which has low effectiveness and high toxicity.
- Poly (ADP-ribose) polymerase (PARP) inhibitors, like olaparib, show promise in treating certain lung cancers, with some trials suggesting benefits for patients with specific mutations.
- A case study of a 27-year-old woman with ALK-positive metastatic lung cancer indicated that combining lorlatinib (an ALK TKI) and olaparib led to a rapid response and improved progression-free survival, highlighting the potential of this combination therapy for further research.
The landscape of kinase domain duplication in Chinese lung cancer patients.
Ann Transl Med
December 2020
Article Synopsis
- The study focuses on kinase domain duplication (KDD) in non-small cell lung cancer (NSCLC) among Chinese patients who lack classic lung cancer driver mutations.
- Researchers analyzed data from over 10,500 lung cancer patients, using genetic sequencing to identify large genomic rearrangements (LGR) and KDD in protein kinase genes.
- Among the cohort, KDD was found in 0.23% of patients, primarily affecting specific exons within the driver genes, with no significant differences in prevalence between lung adenocarcinoma and squamous cell carcinoma cases.